Sorry, you need to enable JavaScript to visit this website.

SPRAVATO® Clinical Trial Studies | SPRAVATO® (esketamine) Nasal Spray
Person with light blue shirt
Actor portrayal.

Proven Effective for
Treatment-Resistant Depression

You may benefit from adding SPRAVATO® to your existing oral antidepressant if you’re an adult with major depressive disorder (MDD) who has had an inadequate response to two or more oral antidepressants, known as treatment-resistant depression (TRD).

Person nose-to-nose with cat
Actor portrayal.

Adults with treatment-resistant depression who were part of a clinical study were given either a nasal esketamine spray or a placebo spray.

Those who added esketamine, the active ingredient in SPRAVATO®, to their oral antidepressant experienced a greater reduction of depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant.*

*Based on an overall score on a standardized rating scale.
4 weeks highlighted in calendar

The SPRAVATO® short-term study lasted four weeks.

  • In a short-term study, more patients using SPRAVATO® plus oral antidepressant demonstrated rapid and superior reduction in depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant
  • Most of the reduction in depressive symptoms was seen at 24 hours
  • Between 24 hours and four weeks, both groups continued to improve; the difference in improvement between the groups remained but did not appear to increase through four weeks
Two arrows pointing right orange icon

SPRAVATO® was also studied in a long-term maintenance-of-effect trial

  • The trial compared patients who stayed on SPRAVATO® and oral antidepressant vs placebo and oral antidepressant long-term
  • Patients who stayed on SPRAVATO® were less likely to experience a return in depressive symptoms (known as relapse)
SPRAVATO® Nasal Spray Device

If two or more oral antidepressants haven’t worked for you, ask your doctor if adding SPRAVATO® may be able to help.